-
Founded in:
2005-02-22 -
Country:
China -
Address:
No. 669, Changjiang West Road, High-tech Zone, Hefei City, Anhui Province -
Tax NO.:
91340000771133813K -
Registered Funds:
89.66 million yuan -
Email:
| Name | Description | Content | CAS NO. | Registered Holders |
|---|---|---|---|---|
| LEVOFLOXACIN LACTATE |
This product is the levorotatory form of ofloxacin, and its antibacterial activity is about 2 times that of ofloxacin. Its main mechanism of action is to inhibit bacterial DNA gyrase activity and inhibit bacterial DNA replication. It has the characteristics of broad antibacterial spectrum and strong antibacterial effect. It has strong antibacterial activity against most Enterobacteriaceae, such as Klebsiella pneumoniae, Proteus, Salmonella typhi, Shigella, influenza bacillus, some Escherichia coli, Pseudomonas aeruginosa, gonococci, etc. It also has good antibacterial effect against some Staphylococci, Streptococcus pneumoniae, Chlamydia, etc.
More
This product is the levorotatory form of ofloxacin, and its antibacterial activity is about 2 times that of ofloxacin. Its main mechanism of action is to inhibit bacterial DNA gyrase activity and inhibit bacterial DNA replication. It has the characteristics of broad antibacterial spectrum and strong antibacterial effect. It has strong antibacterial activity against most Enterobacteriaceae, such as Klebsiella pneumoniae, Proteus, Salmonella typhi, Shigella, influenza bacillus, some Escherichia coli, Pseudomonas aeruginosa, gonococci, etc. It also has good antibacterial effect against some Staphylococci, Streptococcus pneumoniae, Chlamydia, etc. |
294662-18-3 | 11 |
| Name | Description | Content | CAS NO. | Registered Holders |
|---|---|---|---|---|
| LEVOFLOXACIN LACTATE |
This product is the levorotatory form of ofloxacin, and its antibacterial activity is about 2 times that of ofloxacin. Its main mechanism of action is to inhibit bacterial DNA gyrase activity and bacterial DNA replication. It has the characteristics of broad antibacterial spectrum and strong antibacterial effect. It has strong antibacterial activity against most Enterobacteriaceae, such as Klebsiella pneumoniae, Proteus, Salmonella typhi, Shigella, influenza bacillus, some Escherichia coli, Pseudomonas aeruginosa, and gonococci; it also has good antibacterial effect against some Staphylococci, Streptococcus pneumoniae, Chlamydia, etc.
More
This product is the levorotatory form of ofloxacin, and its antibacterial activity is about 2 times that of ofloxacin. Its main mechanism of action is to inhibit bacterial DNA gyrase activity and bacterial DNA replication. It has the characteristics of broad antibacterial spectrum and strong antibacterial effect. It has strong antibacterial activity against most Enterobacteriaceae, such as Klebsiella pneumoniae, Proteus, Salmonella typhi, Shigella, influenza bacillus, some Escherichia coli, Pseudomonas aeruginosa, and gonococci; it also has good antibacterial effect against some Staphylococci, Streptococcus pneumoniae, Chlamydia, etc. |
294662-18-3 | 11 |
| Name | Description | Content | CAS NO. | Registered Holders |
|---|---|---|---|---|
| Curcuma oil |
It has a direct inhibitory effect on respiratory syncytial virus (RSV) and a direct inactivation effect on influenza virus A1 and A3. It has no local irritation and hemolysis in vivo. The LD50 of intravenous injection in mice is 122.14±41.44mg/kg; the LD50 of oral gavage in mice is 147.0g/kg; the LD50 of intramuscular injection is 55g/kg; the maximum tolerance and minimum lethal dose in mice are 48 and 49g/kg respectively. No accumulation effect is observed after six consecutive days of medication.
More
It has a direct inhibitory effect on respiratory syncytial virus (RSV) and a direct inactivation effect on influenza virus A1 and A3. It has no local irritation and hemolysis in vivo. The LD50 of intravenous injection in mice is 122.14±41.44mg/kg; the LD50 of oral gavage in mice is 147.0g/kg; the LD50 of intramuscular injection is 55g/kg; the maximum tolerance and minimum lethal dose in mice are 48 and 49g/kg respectively. No accumulation effect is observed after six consecutive days of medication. |
8024-37-1 | 1 |
| Name | Description | Content | CAS NO. | Registered Holders |
|---|---|---|---|---|
| Notoginseng triterpenes |
Dilate coronary and peripheral blood vessels, reduce peripheral resistance, slow heart rate, reduce and lower myocardial oxygen consumption, increase myocardial perfusion, increase cerebral blood flow, improve myocardial and cerebral ischemia; inhibit platelet aggregation, reduce blood viscosity, inhibit thrombosis; lower blood lipids, resist fatigue, tolerate hypoxia, improve and enhance macrophage function.
More
Dilate coronary and peripheral blood vessels, reduce peripheral resistance, slow heart rate, reduce and lower myocardial oxygen consumption, increase myocardial perfusion, increase cerebral blood flow, improve myocardial and cerebral ischemia; inhibit platelet aggregation, reduce blood viscosity, inhibit thrombosis; lower blood lipids, resist fatigue, tolerate hypoxia, improve and enhance macrophage function. |
88105-29-7 | 0 |